Description: Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Home Page: www.medicenna.com
MDNA Technical Analysis
2 Bloor Street West
Toronto,
ON
M4W 3E2
Canada
Phone:
416 648 5555
Officers
| Name | Title |
|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, Pres & CEO |
| Ms. Rosemina Merchant B.Sc., M.E.Sc | Founder, Chief Devel. Officer & Director |
| Ms. Elizabeth Williams C.A., CPA, CA, CPA | CFO & Corp. Sec. |
| Dr. Martin Bexon M.D., MBBS | Acting Chief Medical Officer & Head of Clinical Devel. |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 208.3333 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3961 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2001-08-27 |
| Fiscal Year End: | March |
| Full Time Employees: | 18 |